The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Open accessAbstract
BACKGROUND: Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. METHODS: ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was a prospective, randomized, double-blind trial. Hospitalized patients with cIAI received either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours or meropenem (1 g) every 8 hours intravenously for 4-14 days. The prospectively defined objectives were to demonstrate statistical noninferiority in clinical cure rates at the test-of-cure visit (24-32 days from start of therapy) in the microbiological intent-to-treat (primary) and microbiologically evaluable (secondary) populations using a noninferiority margin of 10%. Microbiological outcomes and safety were also evaluated. RESULTS: Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389] vs 87.3% [364/417]; weighted difference, -4.2%; 95% confidence interval [CI], -8.91 to .54) and secondary (94.2% [259/275] vs 94.7% [304/321]; weighted difference, -1.0%; 95% CI, -4.52 to 2.59) endpoints, meeting the prespecified noninferiority margin. In patients with ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 100% (13/13) and 72.7% (8/11) in patients with CTX-M-14/15 ESBLs. The frequency of adverse events (AEs) was similar in both treatment groups (44.0% vs 42.7%); the most common AEs in either group were nausea and diarrhea. CONCLUSIONS: Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, including infections caused by multidrug-resistant pathogens. CLINICAL TRIALS REGISTRATION: NCT01445665 and NCT01445678.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Self-citationKumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
Woerther, P.-L., Burdet, C., Chachaty, E., & Andremont, A. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-13 · Cited by 686
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Surgical Infections · doi:10.1089/sur.2009.9930 · Cited by 623
Self-citationMicek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1306-1311.2005 · Cited by 526
Vardakas, K. Z., Tansarli, G. S., Rafailidis, P. I., & Falagas, M. E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks301 · Cited by 354
Proliferation and significance of clinically relevant β‐lactamases
Bush, K. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12023 · Cited by 337
Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study
Sartelli, M., Catena, F., Ansaloni, L., Coccolini, F., Corbella, D., Moore, E. E., Malangoni, M., Velmahos, G., Coimbra, R., Koike, K., et al. (2014) · World Journal of Emergency Surgery · doi:10.1186/1749-7922-9-37 · Cited by 313
Morrissey, I., Hackel, M., Badal, R., Bouchillon, S., Hawser, S., & Biedenbach, D. (2013) · Pharmaceuticals · doi:10.3390/ph6111335 · Cited by 255
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Farrell, D. J., Flamm, R. K., Sader, H. S., & Jones, R. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-13 · Cited by 203
File, T. M., Low, D. E., Eckburg, P. B., Talbot, G. H., Friedland, H. D., Lee, J., Llorens, L., Critchley, I. A., Thye, D. A., on behalf of the FOCUS 1 investigators, et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr096 · Cited by 197
Low, D. E., File, T. M., Eckburg, P. B., Talbot, G. H., David Friedland, H., Lee, J., Llorens, L., Critchley, I. A., Thye, D. A., on behalf of the FOCUS 2 investigators, et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr097 · Cited by 185
Solomkin, J. S., Yellin, A. E., Rotstein, O. D., Christou, N. V., Dellinger, E. P., Tellado, J. M., Malafaia, O., Fernandez, A., Choe, K. A., Carides, A., et al. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000048551.32606.73 · Cited by 182
Self-citationOliva, M. E., Rekha, A., Yellin, A. E., Pasternak, J., Campos, M., Rose, G. M., Babinchak, T., Ellis‐Grosse, E. J., Loh, E., & the 301 Study Group (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-88 · Cited by 153
Sader, H. S., Farrell, D. J., Castanheira, M., Flamm, R. K., & Jones, R. N. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku184 · Cited by 149
LUCASTI, C. J., Hershberger, E., Miller, B. W., Yankelev, S., Steenbergen, J. N., Friedland, I. R., & Solomkin, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00049-14 · Cited by 114
Self-citationSturkenboom, M., Goettsch, W., Picelli, G., Veld, B. I., Yin, D., de Jong, R. B., Go, P. M. N. Y. H., & Herings, R. M. C. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02443.x · Cited by 98
Sader, H. S., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2014) · Journal of Infection · doi:10.1016/j.jinf.2014.04.004 · Cited by 88
Longitudinal Outcomes of Intra-abdominal Infection Complicated by Critical Illness
Barie, P. S., Hydo, L. J., & Eachempati, S. R. (2004) · Surgical Infections · doi:10.1089/sur.2004.5.365 · Cited by 66
Self-citationEdelsberg, J., Berger, A., Schell, S. R., Mallick, R., Kuznik, A., & Oster, G. (2008) · Surgical Infections · doi:10.1089/sur.2006.100 · Cited by 63
Treatment of complicated intra-abdominal infections in the era of multi-drug resistant Bacteria
Herzog, T., Chromik, A., & Uhl, W. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-12-525 · Cited by 53
Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial Proportions
Yan, X., & Su, X. G. (2009) · Statistics in Biopharmaceutical Research · doi:10.1198/sbr.2009.0049 · Cited by 51
Source Control for Surgical Infections
Schein, M., & Marshall, J. K. (2004) · World Journal of Surgery · doi:10.1007/s00268-004-7505-2 · Cited by 49
Minimum risk weights for comparing treatments in stratified binomial trials
Mehrotra, D. V., & Railkar, R. A. (2000) · Statistics in Medicine · Cited by 44
Baré, M., Castells, X., Garcia, A., Riu, M., Comas, M., & Egea, M. J. G. (2006) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462306051063 · Cited by 42
Vindel, A., Trincado, P., Cuevas, Ó., Ballesteros, C., Bouza, E., & Cercenado, E. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku232 · Cited by 40
Qvist, N., Warren, B., Leister-Tebbe, H. K., Zito, E. T., Pedersen, R. D., McGovern, P. C., & Babinchak, T. (2012) · Surgical Infections · doi:10.1089/sur.2011.048 · Cited by 38
Walkty, A. J., Karlowsky, J. A., Adam, H. J., Baxter, M. R., Lagacé-Wiens, P. R. S., Hoban, D. J., & Zhanel, G. G. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01404-13 · Cited by 37
Pseudomonas aeruginosa Post-Operative Peritonitis: Clinical Features, Risk Factors, and Prognosis
Augustin, P., Tran‐Dinh, A., Valin, N., Desmard, M., Crevecoeur, M. A., Muller‐Serieys, C., Woerther, P., Marmuse, J., Bronchard, R., & Montravers, P. (2013) · Surgical Infections · doi:10.1089/sur.2012.084 · Cited by 20
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Metadata
- Authors
- Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., & Eckmann, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-02-10
- Volume
- 60
- Issue
- 10
- Pages
- 1462-1471
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1969500929
- Cited by
- 420
- References
- 36
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.